An Overview of Career Profile of David McDonald of OSI Group

David McDonald has played critical role of leading OSI Group great success over the last few decades. Currently, David serves as the President & COO of OSI Group, a position he has held since the late 1980s. OSI Group is a leading food production company based in Aurora, Illinois, but has over 50 branches in 17 different countries. The company supplies food products like beef patties, sausages, pizza and sandwiches to leading retail brands and food service outlets all over the world.

All employee of OSI Group committed to addressing fully their customers’ expectations. According to David McDonald, the company remains flexible when offering its services. He believes the company has achieved tremendous success because they have managed to establish strong partnerships with other businesses across the world. For instance, OSI Group has operated in China for the more than 20 years now.

David McDonald pursued his education at Iowa State University where he received a degree in animal science. As the President and Chief Operating Officer, David also oversees the company’s operations in Australia. He is also in charge strategic planning and setting at the company. He has played vital role of ensuring both local and global operations of the company are coordinated appropriately by the logistics team. It is an effective strategy implemented by the company to ensure market needs are met. Through this plan, OSI Group was involved in acquisition of Baho Food in order to expand its operations and also customer base. McDonald has also led the company to launching new branches and operations in different parts of the world.

According to David McDonald, the acquisition of Baho Food was a strategy for the company to expand its operations in European countries and serve more customers. Some products supplied by Baho are complementary to OSI’s products, implying their demand would increase. Under the leadership of David McDonald, OSI Group has continued to prove to world that it is the ultimate industry leader. David is involved with Iowa State University Foundation as well as serving on the board of Marfig Global Foods S.A and North America Meat Institute.

Learn More: www.osigroup.com/wp-content/uploads/Flagship-Europe-Press-Release.pdf

Dr. Clay Siegall’s Contribution to Oncology

Dr. Clay Siegall is one of the respected scientists in the United States. He currently works as the chairman and president of the biggest biotechnology company in the US, known as Seattle Genetics. The biotechnology company specializes in the commercialization and development of antibody therapies for cancer treatment. As the president of Seattle Genetics, Clay Siegall has played a fundamental role in the development of antibody drug conjugates. The first ADC product from the firm, known as ADCETRIS, was approved by FDA in the year 2011.

Seattle Genetics has also partnered with Takeda Pharmaceutical Company to market ADCETRIS to more than sixty nations. At the moment, the drug has won the hearts of many because of its ability to cure cancer. Many individuals have benefited from the product. As the chairman of the board at Seattle Genetics, Clay Siegall is responsible for the capital raising activities. Just recently, the private biotechnology company announced to the world that it had successfully managed to raise over one billion dollars in private and public finances. The money will be used to advance cancer treatment. The money raised will also be used to increase the employees working in the institution. In five years, the company will have increased cancer therapies for different types of cancers.

Why Dr. Clay Siegall started Seattle Genetics

Dr. Clay Siegall chose to establish Seattle Genetics to help individuals living with cancer. The scientist watched as his father suffered and finally lose his life due to the dangerous diseases. During the entire process, the scientist realized that there were very few cancer treatment options for individuals with the disease. He also realized that the form of therapy used on patients was not safe, and patients better and more efficient drugs. For the last thirty years, Clay Siegall has been focusing on making his dream to come true.

Clay Siegall Background

Before starting the biotechnology firm, Siegall was serving at Bristol Meter and several other research institutes. His contributions in these companies is recognized up to date. Clay studied Zoology at the University of Maryland. He later went for masters in Genetics in one of the prestigious universities in the world.